C81.22 Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes

Name of the Condition

• Mixed Cellularity Hodgkin Lymphoma, Intrathoracic Lymph Nodes (ICD-10: C81.22)

Summary

Mixed cellularity Hodgkin lymphoma is a subtype of Hodgkin lymphoma characterized by a heterogeneous mix of cell types within affected lymph nodes. It is one of the classical Hodgkin lymphoma subtypes, distinguished by the presence of Reed-Sternberg cells and a variable inflammatory background. This subtype typically presents with widespread lymph node involvement and may affect other lymphoid tissues or organs. The "intrathoracic lymph nodes" designation specifies the anatomical location of the lymphoma, which includes lymph nodes within the chest cavity.

Causes

The exact cause of mixed cellularity Hodgkin lymphoma is not fully understood, but it is associated with genetic mutations and immune system dysregulation. Epstein-Barr virus (EBV) infection is frequently linked to this subtype, suggesting a potential role in its development. Other contributing factors may include genetic predisposition and environmental exposures, though specific triggers remain under investigation.

Risk Factors

• Age: Most common in adults, with a peak incidence in the 30-50 age range.
• Gender: Slightly more prevalent in males.
• Epstein-Barr virus infection: Prior exposure increases risk.
• Immune system suppression: Conditions like HIV/AIDS or immunosuppressive therapy may elevate susceptibility.
• Family history: A first-degree relative with lymphoma may increase risk.

Symptoms

• Painless swelling of lymph nodes, often in the chest or neck
• Persistent cough or shortness of breath (if intrathoracic nodes are involved)
• Fever, night sweats, or unexplained weight loss
• Fatigue or general malaise

Diagnosis

Diagnosis typically involves a combination of clinical evaluation, imaging studies (e.g., CT scans or PET scans), and biopsy of affected lymph nodes. Histopathological examination confirms the presence of Reed-Sternberg cells and the mixed cellularity pattern. Staging procedures assess the extent of disease, including involvement of intrathoracic lymph nodes or other sites.

Treatment Options

Treatment depends on the stage and extent of disease but often includes chemotherapy, sometimes combined with radiation therapy. Common regimens may involve ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or other protocols. Stem cell transplantation may be considered for relapsed or refractory cases.

Prognosis and Follow-Up

Prognosis varies based on stage, response to treatment, and individual factors. Early-stage disease generally has a favorable outcome with standard therapy. Follow-up care includes regular monitoring for recurrence, imaging, and blood tests to assess treatment response and detect late effects.

Complications

• Disease progression or relapse
• Treatment-related side effects (e.g., cardiotoxicity, pulmonary toxicity)
• Secondary malignancies (e.g., leukemia, other lymphomas)
• Long-term immune system effects

Lifestyle & Prevention

• Maintain a healthy lifestyle to support immune function.
• Avoid known environmental risk factors (e.g., smoking, excessive alcohol).
• Stay up-to-date with vaccinations, especially if immunosuppressed.
• Follow recommended screening for high-risk individuals.

When to Seek Professional Help

Seek medical attention for persistent symptoms such as unexplained weight loss, night sweats, fever, or swollen lymph nodes. Prompt evaluation is important for early diagnosis and treatment.

Tips for Medical Coders

Document the specific anatomical location (intrathoracic lymph nodes) to support the C81.22 code. Ensure clinical documentation aligns with the diagnosis and staging details. Verify that the code is used only when the location is explicitly documented as intrathoracic.